This proposal addresses a new approach to cancer treatment that may allow for selective killing of tumor cells regardless of their proliferative status, with potential for fully destroying the tumor. This approach is based on our functional genomic study that revealed that the expression of C0PZ2, a gene encoding a subunit of the coatomer protein complex I (COPI) is drastically decreased in the majority of the tested tumor cell lines and in human cancer tissues. The loss of C0PZ2 expression is a corollary of tumor-specific downregulation of a tumor-suppressive miRNA, miR-152. As a result of miR-152/COPZ2 downregulation, tumor cells become dependent on COPZ1, a gene that encodes an isoform of C0PZ2. While normal C0PZ2-expressing cells survive COPZ1 depletion, C0PZ2-deficient tumor cells are killed by COPZ1 knockdown. Cell death induced by COPZ1 inhibition is associated with Golgi fragmentation and, in contrast to the effects of almost all the anticancer drugs, is independent of cell proliferation. Hence, COPZ1-targeting therapy of miR152-deficient tumors has the potential for eradicating all the cancer cells in the body. We propose a set of specific aims to delineate the tumor-promoting effects of miR-152 down regulation and the frequency of miR-152/COPZ2 silencing in clinical cancers, and to investigate the potential toxicity of COPZ1 inhibition and the feasibility of targeting COPZ1 with small molecules.
In Aim 1, we will identify target genes of miR-152 and analyze their effects on tumor progression.
In Aim 2, we will analyze expression of COPZ1, C0PZ2, miR-152 and miR-152 target genes in clinical samples of malignant melanoma and prostate cancer.
In Aim 3, we will generate mice with homozygous or heterozygous knockout of COPZ1 to determine the deleterious effects of COPZ1 depletion. We will also develop and test prototype COPZ1-targeting small molecules through rational drug design. The success of this project will elucidate the spectrum and properties of miR-152-deficient tumors and provide proof of principle for the eradication of such tumors through therapeutic targeting of COPZ1.

Public Health Relevance

This proposal addresses a new approach to cancer treatment that may allow for selective killing of tumor cells regardless of their proliferative status, with potential for fully destroying the tumor, by attacking a novel molecular target, COPZ1. The proposed study will investigate the feasibility of COPZ1 targeting in cancer treatment and develop the first small-molecule COPZ1 inhibitors.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Exploratory Grants (P20)
Project #
1P20GM109091-01
Application #
8653309
Study Section
Special Emphasis Panel (ZGM1-TWD-A (C1))
Project Start
Project End
Budget Start
2014-07-10
Budget End
2015-04-30
Support Year
1
Fiscal Year
2014
Total Cost
$214,170
Indirect Cost
$64,170
Name
University of South Carolina at Columbia
Department
Type
DUNS #
041387846
City
Columbia
State
SC
Country
United States
Zip Code
29208
Lunev, Sergey; Semmelink, Marije F W; Xian, Jia Ling et al. (2017) Crystal structure of truncated human coatomer protein complex subunit ?1 (Cop?1). Acta Crystallogr F Struct Biol Commun 73:1-8
McDermott, Martina S J; Chumanevich, Alexander A; Lim, Chang-Uk et al. (2017) Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer. Oncotarget 8:12558-12575
Chen, Mengqian; Liang, Jiaxin; Ji, Hao et al. (2017) CDK8/19 Mediator kinases potentiate induction of transcription by NF?B. Proc Natl Acad Sci U S A 114:10208-10213
Vassoler, Fair M; Oliver, David J; Wyse, Cristina et al. (2017) Transgenerational attenuation of opioid self-administration as a consequence of adolescent morphine exposure. Neuropharmacology 113:271-280
Varadaraj, Archana; Jenkins, Laura M; Singh, Priyanka et al. (2017) TGF-? triggers rapid fibrillogenesis via a novel T?RII-dependent fibronectin-trafficking mechanism. Mol Biol Cell 28:1195-1207
Oliver, David; Ji, Hao; Liu, Piaomu et al. (2017) Identification of novel cancer therapeutic targets using a designed and pooled shRNA library screen. Sci Rep 7:43023
Choi, Ran Hee; McConahay, Abigail; Jeong, Ha-Won et al. (2017) Tribbles 3 regulates protein turnover in mouse skeletal muscle. Biochem Biophys Res Commun 493:1236-1242
Markoutsa, Eleni; Xu, Peisheng (2017) Redox Potential-Sensitive N-Acetyl Cysteine-Prodrug Nanoparticles Inhibit the Activation of Microglia and Improve Neuronal Survival. Mol Pharm 14:1591-1600
Yu, Jin; Zhu, Hong; Perry, Stephen et al. (2017) Daily supplementation with GrandFusion® improves memory and learning in aged rats. Aging (Albany NY) 9:1041-1054
He, Huacheng; Markoutsa, Eleni; Zhan, Yihong et al. (2017) Mussel-inspired PLGA/polydopamine core-shell nanoparticle for light induced cancer thermochemotherapy. Acta Biomater 59:181-191

Showing the most recent 10 out of 36 publications